Restless Legs Syndrome Market to Reach $2.5 Billion by 2035

Restless legs syndrome market is projected to grow from $1.4 billion in 2025 to $2.5 billion by 2035, expanding at a CAGR of 6.1% during the forecast period. The market growth is primarily driven by increasing prevalence of neurological and sleep-related disorders, rising awareness regarding Restless Legs Syndrome (RLS), and growing adoption of advanced pharmacological therapies for symptom management and sleep improvement. A key macro driver influencing the market is the growing global burden of sleep disorders and neurological conditions. According to the World Health Organization (WHO) and National Institutes of Health (NIH), sleep disorders and chronic neurological diseases are increasing significantly due to ageing populations, lifestyle changes, stress, and chronic health conditions such as Parkinson’s disease, diabetes, kidney disorders, and iron deficiency anaemia, all of which are closely associated with Restless Legs Syndrome. Additionally, increasing awareness regarding the impact of sleep disorders on mental health, productivity, and quality of life is encouraging higher diagnosis and treatment rates globally.

Browse the full report description of “Restless Legs Syndrome Market Size, Share & Trends Analysis Report, By Treatment (Pharmacological Treatment, Dopamine Agonists, Alpha-2-Delta Calcium Channel Ligands, Iron Supplementation Therapy, Opioid-Based Therapy, Benzodiazepines & Sedative-Hypnotics, Combination Therapy), By Route Of Administration (Oral, Transdermal, Injectable / Infusion), By Drugs Classes (Dopaminergic Agents, Anticonvulsants, Opioids, Iron Replacement Therapies, Sedatives & Sleep Aids), By Distribution (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies / E-Pharmacies, Specialty Pharmacies), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/restless-legs-syndrome-market

From a treatment standpoint, pharmacological therapies continue to dominate the market due to their effectiveness in controlling symptoms and improving sleep quality. Dopamine agonists remain one of the most widely prescribed therapies for moderate-to-severe RLS, while alpha-2-delta calcium channel ligands are witnessing strong demand because of their lower risk of augmentation and improved patient tolerability. Iron supplementation therapies are also gaining traction, particularly among patients with iron deficiency-associated RLS. This growing treatment adoption directly supports market expansion across hospital, retail, and online pharmacy channels. Among drug classes, dopaminergic agents represent the leading segment due to their strong clinical effectiveness in reducing leg discomfort, urge-to-move symptoms, and sleep disturbances. Several strategic developments have further strengthened the market landscape. Key industry developments include:

• In April 2025, Arbor Pharmaceuticals (now part of Aditum Bio) announced expanded access programs and updated prescribing-support materials for its branded gabapentin enacarbil (Horizant®) in the U.S., positioning it as a preferred non-dopaminergic option for moderate-to-severe Restless Legs Syndrome in line with updated clinical-guideline recommendations.

• In November 2024, UCB rolled out a new digital-support platform linked to Neupro® (rotigotine transdermal patch) for Restless Legs Syndrome in selected European markets, offering patient-tracking tools, dosing reminders, and clinician portals to improve long-term adherence and safety monitoring. These developments reflect a strong industry focus on product accessibility, neurological therapy innovation, and expansion of patient-centric treatment solutions to meet growing global demand.

Market Coverage

• The market number available for – 2025-2035
  • Base year- 2025
  • Forecast period- 2026-2035
  • Segment Covered-
  o By Treatment
  o By Route Of Administration
  o By Drug Classes
  o By Distribution
  • Competitive Landscape – UCB S.A., Azurity Pharmaceuticals, LLC, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, and Teva Pharmaceutical Industries Ltd.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Restless Legs Syndrome Market Report Segment

By Treatment

• Pharmacological Treatment
• Dopamine Agonists
• Alpha-2-Delta Calcium Channel Ligands
• Iron Supplementation Therapy
• Opioid-Based Therapy
• Benzodiazepines & Sedative-Hypnotics
• Combination Therapy

By Route Of Administration

• Oral
• Transdermal
• Injectable / Infusion

By Drugs Classes

• Dopaminergic Agents
• Anticonvulsants
•  Opioids
• Iron Replacement Therapies
• Sedatives & Sleep Aids

By Distribution

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies / E-Pharmacies
• Specialty Pharmacies

Global Restless Legs Syndrome Market Report Segment by Region
North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/restless-legs-syndrome-market